Long-term Erythrocytapheresis Is Associated With Reduced Liver Iron Concentration in Sickle Cell Disease

Myers, Scott A.; Eid, Ryan; Myers, John; Bertolone, Salvatore; Panigrahi, Arun; Mullinax, Jennifer; Raj, Ashok

doi:10.1097/mph.0000000000000461

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While differences exist in the pathophysiology of iron overload between SCD and beta-thalassemia major or diseases causing bone marrow failure, the treatment is not significantly different. The incidence of iron overload-associated cardiomyopathy is lower in patients with SCD [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…In the ESRD setting, the increased production of hepcidin decreases iron bioavailability [ 6 ]. Serum ferritin is extensively used to measure iron loading from chronic transfusion because it is standardized, economical, and readily accessible [ 7 ]. But data from national STOP (Stroke Prevention Trial in Sickle Cell Anemia) trials suggest that the correlation between serum ferritin and liver iron concentration (LIC) is not optimal [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease

Raj¹,

McGowan²,

Knapp³

et al. 2022

Cureus

View full text Add to dashboard Cite

Patients with transfusion‐dependent sickle cell disease (SCD) are at risk of iron overload and its complications. Iron overload is a significant risk factor for chronic liver disease in patients who are dependent on hemodialysis secondary to end-stage renal disease (ESRD). Deferasirox is being increasingly used as an iron-chelating agent for the treatment of iron overload in both adults and children. There are limited reports on its use in pediatric patients with ESRD. Here, we discuss the use of deferasirox to treat iron overload in a 15-year-old male with SCD, ESRD from granulomatosis with polyangiitis, and dependent on hemodialysis. We also review the literature on similar uses of deferasirox in adult patients with ESRD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease

Raj¹,

McGowan²,

Knapp³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

Myocardial Iron Overload in Sickle Cell Disease: A Rare But Potentially Fatal Complication of Transfusion

Tavares

Benites

Fertrin

2019

Transfusion Medicine Reviews

View full text Add to dashboard Cite

Long-term Erythrocytapheresis Is Associated With Reduced Liver Iron Concentration in Sickle Cell Disease

Abstract: There was no significant correlation between duration of LTE maintenance and LIC.

Cited by 2 publications

References 21 publications

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease

Myocardial Iron Overload in Sickle Cell Disease: A Rare But Potentially Fatal Complication of Transfusion

Contact Info

Product

Resources

About